Table 1.
Summary of preparations and applications of the protein-biomineralized MOFs.
| MOF | Protein | Size | Application | Ligand | Metal ion | Temperature | Time | Ref. |
|---|---|---|---|---|---|---|---|---|
| ZIF-8 | BSA, HSA, OVA, HRP, insulin, hemoglobin, lysozyme | 1-5 μm | Bioprocessing or delivery | 2-methylimidazole (BSA) | Zn2+ (BSA) | Rt (BSA) | 12 h (BSA) | 22 |
| ZIF-90 | catalase | ~1.5 μm | Biocatalysis | Dithiodiglycolic acid ( disulfide ) | Mn2+ | 150 ℃ | 24 h | 74 |
| ZIF-8 | GOx | >1 μm | Biocatalysis | 2-methylimidazole | Zn2+ | 4 ℃ | 12 h | 127 |
| NU-1003 | organophosphorus acid anhydrolase (OPAA) | 300 nm (minimum size) | Biocatalysis | benzoicacid | Zr4+ | 80 ℃ | 1 h | 145 |
| ZIF-8 | urease | 120-500 nm | Bioprocessing | 2-methylimidazole | Zn2+ | Rt | Over-night | 146 |
| NPCN-333 | tyrosinase | 100 nm | Biocatalysis and cancer therapy | 4,4',4''-s-triazine-2,4,6-triyl-tribenzoic acid (TATB) | Al3+ | 95 ℃ | 24 h | 147 |
| ZIF-8 | insulin/GOx, GOx/HRP or β-Gal/GOx/HRP | ~ 500 nm | Biocatalysis | 2-methylimid azole (insulin) | Zn2+ (insulin) | / | Over-night | 137, 143 |
| ZIF-8 | BSA (DOX) | 70-110 nm | Cancer drug delivery | 2-methylimidazole | Zn2+ | / | 10 min | 148 |
| ZIF-8 | OVA | ~ 200 nm | Cancer immunotherapy | 2-methylimidazole | Zn2+ | Rt | 10 min | 109 |
| ZIF-8 | BSA | 53-153 nm | Bioprocessing for cancer treatment | 2-methylimidazole | Zn2+ | 30 ℃ | 20 min | 75 |
| ZIF-8 | BSA, cytochrome c or gelonin | < 100 nm | Bioprocessing for cancer treatment | 2-methylimidazole (BSA) | Zn2+ (BSA) | / | 50 min (BSA) |
88 |